newsfilter
← Latest News
GlobeNewswire·

Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP

November 24, 2025 Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) announced today that the University of Bonn, Germany is now actively